Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/21/17 | 8-K | Current report filing |
|
6 | |
| 08/09/17 | 8-K | Current report filing |
|
7 | |
| 07/31/17 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 07/31/17 | 8-K | Current report filing |
|
5 | |
| 07/28/17 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 07/27/17 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
22 | |
| 07/24/17 | DEF 14A | Definitive proxy statements |
|
57 | |
| 07/20/17 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
129 |
| 07/14/17 | 8-K | Current report filing |
|
5 | |
| 07/10/17 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
55 |
